Feng Z, Xiang-Lei Li, Hai-Tao W, Zuo-Pei W, Bao-Li H, Hai-Feng Z, Xiao-Long W, Li L
Department of Thoracic Surgery, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, PR China.
Department of Oncology, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, PR China.
Indian J Cancer. 2015 Dec;52 Suppl 3:E176-8. doi: 10.4103/0019-509X.186574.
The aim of this retrospective study was to evaluate the programmed cell death 1 (PD-1) expression in esophageal squamous cell carcinoma (ESCC) and association with clinical characteristics.
From January 2009 to December 2014, 88 patients with ESCC were retrospectively included in this study. Eighty-eight cancer tissues, 35 paraneoplastic atypical hyperplasia tissues (PAHTs), and 30 relative normal esophageal tissues (RNETs) were collected and tested for expression of PD-1 by immunohistochemistry assay. The PD-1 expression and clinical characteristics of the ESCC patients were evaluated. The prognosis of the ESCC patients was compared between the PD-1 positive and negative patients.
The PD-1 positive rate was 51.2% (45/88), 22.9% (8/35), and 6.7% (2/30) for the cancer tissue, PAHT, and RNET, respectively, with statistical difference (P < 0.05); The PD-1 expression was significantly associated with lymph node metastasis (P < 0.05) and pathology grade (P < 0.05). The median overall survival was 29.8 months and 32.1 months for the PD-1 positive and negative groups without statistical difference (hazard ratio = 1.00, 95% confidence interval = 0.58-1.71, P < 0.05).
PD-1 may play a key role in the process of carcinogenesis of ESCC but not associated with prognosis and overall survival.
本回顾性研究旨在评估程序性细胞死亡蛋白1（PD-1）在食管鳞状细胞癌（ESCC）中的表达及其与临床特征的相关性。
回顾性纳入2009年1月至2014年12月期间88例ESCC患者。收集88例癌组织、35例癌旁非典型增生组织（PAHTs）和30例相对正常食管组织（RNETs），采用免疫组织化学法检测PD-1表达。评估ESCC患者的PD-1表达及临床特征。比较PD-1阳性和阴性患者的ESCC预后。
癌组织、PAHT和RNET的PD-1阳性率分别为51.2%（45/88）、22.9%（8/35）和6.7%（2/30），差异有统计学意义（P<0.05）；PD-1表达与淋巴结转移（P<0.05）和病理分级（P<0.05）显著相关。PD-1阳性和阴性组的中位总生存期分别为29.8个月和32.1个月，差异无统计学意义（风险比=1.00，95%置信区间=0.58-1.71，P<0.05）。
PD-1可能在ESCC的致癌过程中起关键作用，但与预后和总生存期无关。
